These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 12668861)
21. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
22. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
23. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors. Dobesh PP; Latham KA Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642 [TBL] [Abstract][Full Text] [Related]
25. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization]. Rossi ML; Merlini PA Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620 [No Abstract] [Full Text] [Related]
26. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
27. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Young JJ J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003 [No Abstract] [Full Text] [Related]
28. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156 [TBL] [Abstract][Full Text] [Related]
29. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease]. Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681 [TBL] [Abstract][Full Text] [Related]
31. [Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization]. Albuquerque A Rev Port Cardiol; 2001 Sep; 20(9):927-8. PubMed ID: 11763604 [No Abstract] [Full Text] [Related]
32. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention. Anderson JR; Riding D Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812 [TBL] [Abstract][Full Text] [Related]
33. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230 [TBL] [Abstract][Full Text] [Related]
34. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Sabatine MS; Jang IK Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186 [TBL] [Abstract][Full Text] [Related]
35. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions. Gambhir DS; Mukhopadhyay S Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774 [No Abstract] [Full Text] [Related]
36. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970 [TBL] [Abstract][Full Text] [Related]
37. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents. Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994 [TBL] [Abstract][Full Text] [Related]